Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Introduction. Controversy remains over the optimal length of anticoagulation following idiopathic venous thromboembolism. We sought to determine if a longer, finite course of anticoagulation offered additional benefit over a short course in the initial treatment of the first episode of idiopathic venous thromboembolism. Data Extraction. Rates of deep venous thrombosis, pulmonary embolism, combined venous thromboembolism, major bleeding, and mortality were extracted from prospective trials enrolling patients with first time, idiopathic venous thromboembolism. Data was pooled using random effects meta-regression. Results. Ten trials, with a total of 3225 patients, met inclusion criteria. For each additional month of initial anticoagulation, once therapy was stopped, recurrent venous thromboembolism (0.03 (95% CI: −0.28 to 0.35); ), mortality (−0.10 (95% CI: −0.24 to 0.04); ), and major bleeding (−0.01 (95% CI: −0.05 to 0.02); ) rates measured in percent per patient years, did not significantly change. Conclusions: Patients with an initial idiopathic venous thromboembolism should be treated with 3 to 6 months of secondary prophylaxis with vitamin K antagonists. At that time, a decision between continuing with indefinite therapy can be made, but there is no benefit to a longer (but finite) course of therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“several of the studies identified above observed that any benefit associated with a longer finite course of therapy is lost after anticoagulation is discontinued. 257,261”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249 · cited 2×
“of Chest Physicians (ACCP) consensus guidelines updated treatment recommendations for the first episode of idiopathic VTE [2] by modifying their previous recommendation of 6–12 months treatment [5], to “at least three months.”
BackgroundKearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Schulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808 · cited 1×
“Two additional RCTs that enrolled patients with idiopathic VTE but met exclusion criteria, one because several patients in one arm were diagnosed with APAS at enrollment [26] and the other because one third of patients had previous VTE [27], were added back to see if their inclusion would impact our results.”
BackgroundBaglin, T., Luddington, R., Brown, K., & Baglin, C. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14111-6 · Cited by 694
Research works printed but not linked: 3
- 2006, Cochrane Database of Systematic Reviews
- 1999, Statistics in Medicine, 18, 2693, 10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v · doi:10.1002/(sici)1097-0258(19991030)18:20<2693::aid-sim235>3.0.co;2-v
- 2004, Saudi Medical Journal, 25, 848
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“In addition, several of the studies identified above observed that any benefit associated with a longer finite course of therapy is lost after anticoagulation is discontinued.(257,261) The ASH guideline panel provided a conditional recommendation supporting a shorter course (3-6 months) of therapy over a longer durati…”
BackgroundLyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Treatment of Venous Thromboembolism
Wells, P. S., Forgie, M. A., & Rodger, M. A. (2014) · JAMA · doi:10.1001/jama.2014.65 · Cited by 237
Alexander, P., Visagan, S., Issa, R., Gorantla, V. R., & Thomas, S. (2021) · Cureus · doi:10.7759/cureus.18992 · Cited by 46
Prandoni, P., Barbar, S., Milan, M., Vedovetto, V., & Pesavento, R. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.09.005 · Cited by 26
Metadata
- Authors
- Holley, A. B., King, C. S., Jackson, J. L., & Moores, L. K.
- Affiliations
- Walter Reed National Military Medical Center (US)
- William Beaumont Army Medical Center (US)
- Uniformed Services University of the Health Sciences (US)
- Corresponding author
- Holley, Aaron B.
- Venue
- Thrombosis
- Publisher
- Hindawi Limited
- Published
- 2010-12-29
- Volume
- 2010
- Pages
- 1-9
- ISSN
- 2090-1488 (ISSN-L)
- 2090-1496
- PMC
- PMC3211079
- OpenAlex
- W1964425295
- Cited by
- 10
- References
- 33
- Citations by year
- 2025: 1 · 2022: 1 · 2021: 2 · 2020: 1 · 2018: 1 · 2016: 1 · 2014: 2 · 2013: 1
- FWCI
- 0.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Thrombosis (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- idiopathic venous thromboembolism, anticoagulation duration, indefinite anticoagulation, vitamin K antagonists, recurrent venous thromboembolism, pulmonary embolism, deep vein thrombosis, major bleeding, mortality, secondary prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. https://app.cochat.ai/papers/10.1155/2010/540386
- The paper
- Holley, A. B., King, C. S., Jackson, J. L., & Moores, L. K. (2010). Different Finite Durations of Anticoagulation and Outcomes following Idiopathic Venous Thromboembolism: A Meta-Analysis. Thrombosis. https://doi.org/10.1155/2010/540386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.